| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | Compositions and Methods for the Treatment of Hepatic Diseases and Disorders | US13743194 | 2013-01-16 | US20140030194A1 | 2014-01-30 | Elizabeth McKenna |
| The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes. | ||||||
| 22 | Streptococcal C5A peptidase vaccine | US11071041 | 2005-03-03 | US08440205B2 | 2013-05-14 | Paul Patrick Cleary; Deborah K. Stafslien |
| Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 23 | Streptococcal C5a peptidase vaccine | US09870122 | 2001-05-30 | US06951653B2 | 2005-10-04 | Paul Patrick Cleary; Deborah K. Stafslien |
| Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 24 | 肝疾患及び肝障害を治療するための組成物及び方法 | JP2014552395 | 2013-01-16 | JP2015503628A | 2015-02-02 | マッケンナ，エリザベス |
| 本開示は、口腔用組成物と、1種以上の肝障害に罹患した対象の治療に前記組成物を用いる方法を提供する。前記組成物は、C型肝炎ウイルス5型(HCV)に対する特定の活性を示す1種以上のグラム陽性菌の溶解産物若しくは細胞壁抽出物を含み、HCV感染者、及びその他の肝疾患又は肝障害の罹患者の治療に有用であり得る。補体系経路をアップレギュレーション又はダウンレギュレーションできる少なくとも1種の治療活性物質を治療有効量投与することによって、肝疾患又は肝障害を治療する方法であって、前記治療活性物質が1種以上の転換酵素の形成を増大させる方法も説明する。【選択図】図5 | ||||||
| 25 | Streptococcal C5a peptidase vaccine | JP2000586920 | 1999-12-03 | JP5122703B2 | 2013-01-16 | パトリック クリアリー，ポール; ケー． スタッフスリーン，デボラ |
| 26 | Octenidine composition | JP2011237153 | 2011-10-28 | JP2012072153A | 2012-04-12 | CLEARY PAUL PATRICK; STAFSLIEN DEBORAH K |
| PROBLEM TO BE SOLVED: To provide an effective vaccine for immunizing susceptible mammal against β hemolytic streptococcus, and to provide a method for administering the vaccine.SOLUTION: The new vaccines for using against β hemolytic streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). A method of protecting a susceptible mammal against β hemolytic streptococcus colonization or infection by administering such a vaccine is also disclosed. Enzymatically inactive SCP, and polynucleotides encoding the SCP proteins are further disclosed. | ||||||
| 27 | Control of Cellular Redox Levels | US15703611 | 2017-09-13 | US20180064769A1 | 2018-03-08 | Elizabeth McKenna |
| Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents. | ||||||
| 28 | Control of Cellular Redox Levels | US15703608 | 2017-09-13 | US20180064768A1 | 2018-03-08 | Elizabeth McKenna |
| Disclosed herein are compositions and methods for regulating redox status and/or reducing oxidative stress in a subject, the methods and compositions comprising TLR agonists comprising bacterial lysates and/or lysate fractions. Also disclosed are compositions and methods comprising bacterial lysates and/or lysate fractions formulated or administered in combination with one or more other therapeutic or pharmaceutical agents. | ||||||
| 29 | POLYPEPTIDES AND USES THEREOF | US15316458 | 2015-06-05 | US20170210781A1 | 2017-07-27 | MILES NUNN; SUSAN MARY LEA; MATTHIJS MIKLAS JORE |
| The invention relates to polypeptides, and in particular to polypeptides that are capable of inhibiting the activity or activation of the complement system. It also relates to nucleic acids that encode the polypeptides and to uses of the polypeptides.The complement system helps or “complements” the ability of antibodies and phagocytic cells to clear pathogens from an organism. It forms part of the innate immune system. Down-regulation of complement activation has been demonstrated to be effective in treating several disease indications in animal models and in ex vivo studies. The present invention provides novel polypeptides that can be used for the treatment of diseases or disorders that relate to inappropriate activation of one or more of the complement pathways. | ||||||
| 30 | HEPARIN AFFINITY TAG AND APPLICATIONS THEREOF | US15112984 | 2015-01-20 | US20170029461A1 | 2017-02-02 | Suresh Kumar Thallapuranam; Srinivas Jayanthi; Jacqueline Morris; Alicia Brown; David McNabb; Ralph Henry |
| In one aspect, affinity tags for recombinant protein purification are described herein which, in some embodiments, can mitigate or overcome disadvantages of prior affinity tag systems. In some embodiments, for example, affinity tags described herein permit efficient elution of desired recombinant proteins with simplified solution systems, such as alkali metal salt solutions. An affinity tag described herein comprises an amino acid sequence including a repeating amino acid unit of BXXXBXX, wherein B is an amino acid selected from the group consisting of histidine, lysine and arginine and X is an amino acid selected from the group consisting of amino acids other than histidine, lysine and arginine. | ||||||
| 31 | Streptococcal C5a peptidase vaccine | US10915705 | 2004-08-10 | US07635483B2 | 2009-12-22 | Paul Patrick Cleary; Deborah K. Stafslien |
| Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 32 | Streptococcal C5a peptidase vaccine | US11071041 | 2005-03-03 | US20060153879A1 | 2006-07-13 | Paul Cleary; Deborah Stafslien |
| Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 33 | Streptococcal C5a peptidase vaccine | US09870122 | 2001-05-30 | US20040062777A1 | 2004-04-01 | Paul Patrick Cleary; Deborah K. Stafslien |
| Novel vaccines for use against null-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against null-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 34 | Streptococcal C5a peptidase vaccine | US09206898 | 1998-12-07 | US06355255B1 | 2002-03-12 | Paul Patrick Cleary; Deborah K. Stafslien |
| Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of strepococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 35 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEPATIC DISEASES AND DISORDERS | EP13738189 | 2013-01-16 | EP2804613A4 | 2015-12-09 | MCKENNA ELIZABETH |
| The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes. | ||||||
| 36 | Streptococcal C5a peptidase vaccine | EP10185549.2 | 1999-12-03 | EP2308981A1 | 2011-04-13 | Cleary, Paul; Stafslien, Deborah |
Novel vaccines for use against beta -hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against beta -hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
|
||||||
| 37 | Streptococcal C5a peptidase vaccine | EP07015995.9 | 1999-12-03 | EP1892298A1 | 2008-02-27 | Cleary, Paul Patrick; Stafslien, Deborah K. |
Novel vaccines for use against beta -hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against beta -hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.
|
||||||
| 38 | STREPTOCOCCAL C5a PEPTIDASE VACCINE | EP99966013.7 | 1999-12-03 | EP1137785A1 | 2001-10-04 | CLEARY, Paul, Patrick; STAFSLIEN, Deborah, K. |
| Novel vaccines for use against β-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against β-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed. | ||||||
| 39 | 간 질환들 및 장애들의 치료를 위한 조성물들 및 방법들 | KR1020147018038 | 2013-01-16 | KR1020140121818A | 2014-10-16 | 맥켄나,엘라자베스 |
| 본 발명은 하나 이상의 간 장애들을 가진 감염된 개체들을 치료하기 위한 경구적 조성물들 및 이러한 조성물들을 사용하는 방법들을 제공한다. 본 조성물들은 하나 이상의 그램 양성 세균들의 용출물들 또는 세포벽 추출물들을 포함하고, C형 간염 바이러스 제 5형 (HCV)에 대한 특정한 활성을 나타내며, HCV로 감염된 개체들뿐만 아니라 다른 간 질환들 또는 장애들을 치료하는 데 유용할 수 있다. 또한 보체계 (Complement system) 경로로서, 10가지 치료적으로 활성을 가진 제제가 하나 이상의 컨버타제 (convertase) 효소들의 형성을 증진하는 경로를 상승조절 또는 저하조절할 수 있는 적어도 하나의 치료적으로 활성을 가진 제제의 치료적 유효량을 투여함으로써 간 질환 또는 장애를 치료하는 방법들이 기술된다.
|
||||||
| 40 | METHODS AND COMPOSITIONS FOR TREATMENT OF GAUCHER DISEASE VIA MODULATION OF C5A RECEPTOR | EP16847046.6 | 2016-08-29 | EP3349773A1 | 2018-07-25 | PANDEY, Manoj, Kumar |
| Disclosed are compositions and methods for the reduction of C5a mediated immune inflammation. The methods, in various aspects, may include the step of administering a C5aR antagonist to a subject in need of such treatment. In one aspect, the subject in need may have a lysosomal acid storage disease. Therapeutic kits and articles of manufacture are also disclosed. | ||||||
QQ群二维码
意见反馈
意见反馈